These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 8819245

  • 1. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors.
    Singer ST, Addiego JE, Reason DC, Lucas AH.
    Thromb Haemost; 1996 Jul; 76(1):17-22. PubMed ID: 8819245
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects.
    Reding MT, Wu H, Krampf M, Okita DK, Diethelm-Okita BM, Christie BA, Key NS, Conti-Fine BM.
    Thromb Haemost; 2000 Oct; 84(4):643-52. PubMed ID: 11057864
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A.
    Qian J, Borovok M, Bi L, Kazazian HH, Hoyer LW.
    Thromb Haemost; 1999 Feb; 81(2):240-4. PubMed ID: 10063999
    [Abstract] [Full Text] [Related]

  • 6. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
    Lusher JM.
    Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
    Rea C, Dunkerley A, Sørensen B, Rangarajan S.
    Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
    [Abstract] [Full Text] [Related]

  • 12. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.
    Kaveri SV, Dasgupta S, Andre S, Navarrete AM, Repessé Y, Wootla B, Lacroix-Desmazes S.
    Haemophilia; 2007 Dec; 13 Suppl 5():61-4. PubMed ID: 18078399
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.
    Mariani G, Kroner B, Immune Tolerance Study Group (ITSG).
    Haematologica; 2001 Nov; 86(11):1186-93. PubMed ID: 11694405
    [Abstract] [Full Text] [Related]

  • 17. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
    Rubinger M, Lillicrap D, Rivard GE, Teitel J, Carcao M, Hensman C, Walker I, Association of Hemophilia Clinic Directors of Canada.
    Haemophilia; 2008 Mar; 14(2):281-6. PubMed ID: 18194308
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [T cell proliferative response and antibody formation to citrullinated collagen type II in patients with rheumatoid arthritis].
    Tian X, Zhao Y, Li ZG.
    Zhonghua Yi Xue Za Zhi; 2009 Mar 17; 89(10):673-6. PubMed ID: 19595060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.